Following a meeting with regulators in September, Sarepta spelled out a new set of data that the FDA is looking for in the application for its closely watched Duchenne muscular dystrophy drug eteplirsen, and the biotech says it will have to delay filing–another dramatic turning point for the company this year, which saw its shares plunge 30% on the news this morning.

…read more

Source: UPDATED: Sarepta plunges as CEO moves goal line on Duchenne MD drug downfield


0 No comments